(Q48403657)

11 February 2018

title

L-Dopa and schizophrenia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1268799

7 September 2022

L-Dopa and Schizophrenia (English)

1 reference

https://api.crossref.org/works/10.1177/070674377602100105

16 November 2023

1 reference

P. E. Garfinkel

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1268799

7 September 2022

H. C. Stancer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1268799

7 September 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1268799

7 September 2022

publication date

1 February 1976

1 reference

11 February 2018

Canadian Psychiatric Association journal

published in

1 reference

11 February 2018

volume

21

1 reference

11 February 2018

issue

1

1 reference

11 February 2018

page(s)

27-29

1 reference

11 February 2018

A clinical and biochemical study of a trial of iproniazid in the treatment of depression

cites work

1 reference

https://api.crossref.org/works/10.1177%2F070674377602100105

Behavioral effects of l-Dopa in schizophrenic patients

21 January 2018

1

1 reference

https://api.crossref.org/works/10.1177/070674377602100105

Levodopa: Alterations in behavior

16 November 2023

4

1 reference

https://api.crossref.org/works/10.1177/070674377602100105

CLINICAL EXPERIENCE WITH DIHYDROXYPHENYLALANINE (DOPA) IN DEPRESSION

16 November 2023

6

1 reference

https://api.crossref.org/works/10.1177/070674377602100105

16 November 2023

Identifiers

1 reference

11 February 2018

1 reference

11 February 2018